Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Conditions: Mantle Cell Lymphoma

Interventions: Biological: Obinutuzumab; Biological: Glofitamab; Drug: Pirtobrutinib; Procedure: Tumor Imaging; Procedure: Biospecimen Collection; Device: ClonoSeq Assay; Procedure: Bone Marrow Biopsy

Sponsors: C. Babis Andreadis; Eli Lilly and Company; Genentech, Inc.; Adaptive Biotechnologies

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 13, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments